Antiangiogenic therapy also upregulates PD-L1 expression on endothelial cells and tumor cells in mouse breast cancer models [9, 101], which sensitizes the tumor cells to anti-PD-1 therapy [7]. This evidence concerns the gene CD274 and neoplasm.